ZNTL on Nasdaq
Zentalis Pharmaceuticals, Inc.
In its 2026 annual report the company says: “We are a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), an investigational, potentially first-in-class and best-in-class WEE1 inhibitor, for patients with ovarian cancer and other tumor types. We are currently focused on advancing the clinical development of azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer, or PROC.”3 It is headquartered in San Diego, California.1 Its shares trade on Nasdaq under the symbol ZNTL.1
Price unavailable
Last updated Oct 21, 2026.
Overview
Compare with Kura Oncology, Rockwell Medical Inc. or ENANTA PHARMACEUTICALS INC, or pick any stock.
- TickerZNTL on Nasdaq1
- IndustryPharmaceutical Preparations1
- HeadquartersSan Diego, California1
- Business address10275 Science Center Drive, Suite 200, San Diego, Ca 921212
- Filer categoryNon-accelerated filer, Smaller reporting company2
See how the biggest companies compare on our leaderboards
We are a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), an investigational, potentially first-in-class and best-in-class WEE1 inhibitor, for patients with ovarian cancer and other tumor types. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types. We are currently focused on advancing the clinical development of azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer, or PROC. We believe that our DENALI (ZN-c3-005) Part 2 clinical trial of azenosertib in patients with Cyclin E1-positive PROC, if successful, has the potential to support an accelerated approval, subject to U.S. Food and Drug Administration, or FDA, review. Azenosertib also has broad franchise potential beyond Cyclin E1-positive PROC. We exclusively in-license or solely own worldwide development and…3 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Revenues from Licensing and Sales of Intellectual Property | $0 | $67.4M | $0 |
| Research and development | $107.3M | $167.8M | $189.6M |
| Zentera in-process research and development | $0 | $0 | $45.6M |
| General and administrative | $37.7M | $87.1M | $64.4M |
| Restructuring | $7.8M | $0 | $0 |
| Goodwill impairment | $0 | $3.7M | $0 |
| Total operating expenses | $152.8M | $258.6M | $299.5M |
| Loss from operations | -$152.8M | -$191.2M | -$299.5M |
| Investment and other income, net | $16.2M | $25.5M | $22.6M |
| Net loss before income taxes | -$136.6M | -$165.7M | -$276.9M |
| Income tax expense (benefit) | $442.0K | $177.0K | -$601.0K |
| Loss on equity method investment | $0 | $0 | $16.0M |
| Net loss | -$137.1M | -$165.9M | -$292.3M |
| Net loss attributable to noncontrolling interests | $0 | -$28.0K | -$114.0K |
| Net loss attributable to Zentalis | -$137.1M | -$165.8M | -$292.2M |
| Net loss per common share outstanding, basic (in dollars per share) | -$1.91 | -$2.33 | -$4.47 |
| Net loss per common share outstanding, diluted (in dollars per share) | -$1.91 | -$2.33 | -$4.47 |
| Common shares used in computing net loss per share, basic (in shares) | 71.9M shares | 71.1M shares | 65.4M shares |
| Common shares used in computing net loss per share, diluted (in shares) | 71.9M shares | 71.1M shares | 65.4M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $36.0M | $33.9M | $28.0M |
| Marketable debt securities, available for sale | $209.9M | $318.0M | |
| Marketable equity securities | $0 | $19.2M | |
| Contracts receivable | $0 | $5.0M | |
| Prepaid expenses and other current assets | $7.3M | $10.0M | |
| Total current assets | $253.2M | $386.1M | |
| Property and equipment, net | $2.8M | $4.7M | |
| Operating lease right-of-use assets | $26.3M | $32.5M | |
| Prepaid expenses and other assets | $4.1M | $4.4M | |
| Restricted cash | $2.6M | $2.6M | $2.7M |
| Total assets | $289.0M | $430.3M | |
| Accounts payable | $7.2M | $7.4M | |
| Accrued expenses | $29.4M | $45.3M | |
| Total current liabilities | $36.6M | $52.7M | |
| Long-term lease liability | $35.7M | $39.6M | |
| Other long-term liabilities | $500.0K | $849.0K | |
| Total liabilities | $72.8M | $93.2M | |
| Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued and outstanding at December 31, 2025 and 2024 | $0 | $0 | |
| Common stock, $0.001 par value; 250,000,000 shares authorized; 69,085,980 and 71,282,400 shares issued and outstanding at December 31, 2025 and 2024, respectively | $69.0K | $71.0K | |
| Additional paid-in capital | $1.4B | $1.4B | |
| Accumulated other comprehensive income | $196.0K | $558.0K | |
| Accumulated deficit | -$1.2B | -$1.1B | |
| Total stockholders' equity | $216.2M | $337.2M | |
| Total liabilities and stockholders' equity | $289.0M | $430.3M | |
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized (in shares) | 10.0M shares | 10.0M shares | |
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | |
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in shares) | 250.0M shares | 250.0M shares | |
| Common stock, shares issued (in shares) | 69.1M shares | 71.3M shares | |
| Common stock, shares outstanding (in shares) | 69.1M shares | 71.3M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $36.0M | $33.9M | $28.0M |
| Marketable debt securities, available for sale | $209.9M | $318.0M | |
| Marketable equity securities | $0 | $19.2M | |
| Contracts receivable | $0 | $5.0M | |
| Prepaid expenses and other current assets | $7.3M | $10.0M | |
| Total current assets | $253.2M | $386.1M | |
| Property and equipment, net | $2.8M | $4.7M | |
| Operating lease right-of-use assets | $26.3M | $32.5M | |
| Prepaid expenses and other assets | $4.1M | $4.4M | |
| Restricted cash | $2.6M | $2.6M | $2.7M |
| Total assets | $289.0M | $430.3M | |
| Accounts payable | $7.2M | $7.4M | |
| Accrued expenses | $29.4M | $45.3M | |
| Total current liabilities | $36.6M | $52.7M | |
| Long-term lease liability | $35.7M | $39.6M | |
| Other long-term liabilities | $500.0K | $849.0K | |
| Total liabilities | $72.8M | $93.2M | |
| Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued and outstanding at December 31, 2025 and 2024 | $0 | $0 | |
| Common stock, $0.001 par value; 250,000,000 shares authorized; 69,085,980 and 71,282,400 shares issued and outstanding at December 31, 2025 and 2024, respectively | $69.0K | $71.0K | |
| Additional paid-in capital | $1.4B | $1.4B | |
| Accumulated other comprehensive income | $196.0K | $558.0K | |
| Accumulated deficit | -$1.2B | -$1.1B | |
| Total stockholders' equity | $216.2M | $337.2M | |
| Total liabilities and stockholders' equity | $289.0M | $430.3M | |
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized (in shares) | 10.0M shares | 10.0M shares | |
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | |
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in shares) | 250.0M shares | 250.0M shares | |
| Common stock, shares issued (in shares) | 69.1M shares | 71.3M shares | |
| Common stock, shares outstanding (in shares) | 69.1M shares | 71.3M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$137.1M | -$165.9M | -$292.3M |
| Depreciation and amortization | $739.0K | $1.3M | $1.4M |
| Operating lease right-of-use and fixed asset impairment | $4.1M | $0 | $5.0M |
| Noncash consideration portion of Zentera in-process research and development | $0 | $0 | $15.0M |
| Share-based compensation | $20.7M | $67.3M | $54.8M |
| Goodwill impairment | $0 | $3.7M | $0 |
| (Gain)/loss on disposal of equipment | -$660.0K | -$13.0K | $406.0K |
| Non-cash impact of revenues from licensing and sales of intellectual property | $0 | -$47.4M | $0 |
| Non-cash recognized mark-to-market of equity securities | -$1.2M | -$5.2M | $0 |
| Accretion of discounts on marketable securities, net | -$2.8M | -$8.0M | -$13.2M |
| Loss on equity method investment | $0 | $0 | $16.0M |
| Deferred income taxes | $0 | $0 | -$853.0K |
| Deconsolidation of Kalyra | $0 | -$79.0K | $0 |
| Accounts receivable | $5.0M | -$5.0M | $0 |
| Prepaid expenses and other assets | $3.0M | $6.2M | -$5.7M |
| Accounts payable and accrued liabilities | -$17.3M | -$18.0M | $10.9M |
| Operating lease right-of-use assets and liabilities, net | $201.0K | $264.0K | $623.0K |
| Net cash used in operating activities | -$125.2M | -$170.9M | -$207.8M |
| Purchases of marketable debt securities | -$139.5M | -$128.0M | -$549.2M |
| Proceeds from maturities of marketable debt securities | $250.0M | $271.2M | $505.3M |
| Proceeds from sale of marketable equity securities | $20.4M | $33.5M | $0 |
| Proceeds from sale of property and equipment | $698.0K | $65.0K | $0 |
| Purchases of property and equipment | $0 | -$221.0K | -$583.0K |
| Net cash provided by (used in) investing activities | $131.6M | $176.6M | -$44.5M |
| Proceeds from issuance of common stock, net | $5.4M | $0 | $235.7M |
| Proceeds from issuance of common stock under equity incentive plans | $304.0K | $349.0K | $1.6M |
| Repurchase of common stock | -$10.0M | $0 | $0 |
| Net-settlement of restricted stock unit vesting | $0 | -$241.0K | $0 |
| Net cash (used in) provided by financing activities | -$4.3M | $108.0K | $237.3M |
| Net increase (decrease) in cash, cash equivalents and restricted cash | $2.1M | $5.8M | -$15.0M |
| Income taxes paid | $85.0K | $359.0K | $140.0K |
| Right-of-use assets obtained in exchange for operating lease liabilities | $0 | $0 | $602.0K |
No quarter-by-quarter statement was filed.
Corporate structure
Zentalis Pharmaceuticals, Inc. sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Zentalis Pharmaceuticals, Inc.
- WALTERS GROUP Filed SCHEDULE 13G/A on Zentalis Pharmaceuticals, Inc., latest Aug 19, 2026 (2 filings since Jan 5, 2026)
- Barclays Filed SCHEDULE 13G/A on Zentalis Pharmaceuticals, Inc., latest Aug 13, 2026 (2 filings since Nov 12, 2025)
- BlackRock Filed SCHEDULE 13G on Zentalis Pharmaceuticals, Inc., latest Jul 30, 2026 (5 filings since Feb 3, 2022)
- Squadron Capital Management LLC Filed SCHEDULE 13G on Zentalis Pharmaceuticals, Inc., latest Mar 3, 2026
- Matrix Capital Management Company, LP Filed SCHEDULE 13D/A on Zentalis Pharmaceuticals, Inc., latest Jan 2, 2026 (5 filings since Feb 14, 2022)
- 5AM Opportunities II (GP), LLC Filed SCHEDULE 13G on Zentalis Pharmaceuticals, Inc., latest Dec 30, 2025
- MILLENNIUM MANAGEMENT LLC Filed SCHEDULE 13G/A on Zentalis Pharmaceuticals, Inc., latest Oct 14, 2025 (2 filings since Feb 4, 2025)
- EVENTIDE ASSET MANAGEMENT, LLC Filed SCHEDULE 13G/A on Zentalis Pharmaceuticals, Inc., latest May 14, 2025 (6 filings since Oct 10, 2023)
- VANGUARD GROUP INC Filed SCHEDULE 13G/A on Zentalis Pharmaceuticals, Inc., latest Jan 31, 2025 (6 filings since Feb 10, 2022)
- William Thurman Walters Filed SCHEDULE 13G/A on Zentalis Pharmaceuticals, Inc., latest Jan 31, 2025 (4 filings since Dec 10, 2024)
- FMR LLC Filed SCHEDULE 13G/A on Zentalis Pharmaceuticals, Inc., latest Dec 6, 2024 (5 filings since Feb 9, 2022)
- CITADEL ADVISORS LLC Filed SC 13G/A on Zentalis Pharmaceuticals, Inc., latest Nov 14, 2024 (3 filings since Nov 17, 2023)
- Zentalis Pharmaceuticals, Inc. San Diego, California
Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Zentalis Pharmaceuticals, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $5.5M4 Dec 31, 2025 | $9.0M4 Dec 31, 2024 | −38.2% |
| Accumulated depreciation | $2.8M4 Dec 31, 2025 | $4.3M4 Dec 31, 2024 | −35.1% |
| Property and equipment, net | $2.8M4 Dec 31, 2025 | $4.7M4 Dec 31, 2024 | −41.1% |
| Operating-lease assets (leased space) | $26.3M4 Dec 31, 2025 | $32.5M4 Dec 31, 2024 | −19.2% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $36.0M4 Dec 31, 2025 | $33.9M4 Dec 31, 2024 | +6.2% |
| Marketable securities, current | $209.9M4 Dec 31, 2025 | $318.0M4 Dec 31, 2024 | −34.0% |
| Debt securities available for sale | $209.9M4 Dec 31, 2025 | $318.0M4 Dec 31, 2024 | −34.0% |
| Equity securities at fair value | $04 Dec 31, 2025 | $19.2M4 Dec 31, 2024 | −100.0% |
| Stakes in other companies (equity method) | $05 Dec 31, 2024 | $05 Dec 31, 2023 |
Intangibles and goodwill
Properties, in its own words
Our principal executive office is located at 10275 Science Center Drive, Suite 200, San Diego, California 92121, where we lease approximately 56,700 square feet and 17,900 square feet of office and laboratory space, respectively, under a lease that expires in September 2032. We believe that our facilities are sufficient to meet our current needs.
Item 2 of the 10-K filed Mar 26, 2026.3
Leadership
Who has led Zentalis Pharmaceuticals, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
Chief operating officer
2025
- Chief executive officerJulia Marie Eastland Nov 13, 2024 to now12
- Chief executive officerKimberly Blackwell May 20, 2022 to Feb 5, 202413
- PresidentJulia Marie Eastland Nov 13, 2024 to now12
- PresidentKimberly Blackwell May 20, 2022 to May 20, 202213
- PresidentCam Gallagher May 31, 2022 to May 31, 202414
- Chief financial officerCam Gallagher May 31, 2024 to May 31, 202415
- Chief financial officerMelissa B. Epperly Apr 3, 2020 to Feb 12, 202416
- Chief operating officerIris Roth Feb 13, 2023 to Mar 2, 202317
- Chief operating officerKevin D. Bunker Apr 3, 2020 to Aug 12, 202218
Board members and other officers (21)
- Chief Scientific OfficerMark Lackner Jan 3, 2024 to Feb 5, 202519
- Chief Medical OfficerDiana Hausman Feb 5, 2024 to May 9, 202420
- Principal Accounting OfficerVincent Vultaggio Apr 11, 2024 to now21
- Chief Medical OfficerIngmar Bruns Nov 13, 2024 to now22
- Chief Medical OfficerCarrie Brownstein Oct 3, 2022 to Oct 6, 202323
- Chief Scientific OfficerKevin D. Bunker Oct 3, 2022 to Dec 21, 202324
- SVP, Clinical DevelopmentDimitris Voliotis Apr 3, 2020 to Feb 14, 202225
- Board memberShannon Campbell May 27, 2026 to now26
- Board memberLuke Nathaniel Walker May 29, 2024 to now27
- Board memberJulia Marie Eastland Nov 13, 2024 to now12
- Board memberScott Dunseth Myers Nov 13, 2024 to now28
- Board memberDiana Hausman May 10, 2023 to May 10, 202329
- Board memberJan Skvarka Sep 12, 2022 to now30
- Board memberEnoch Kariuki Feb 10, 2021 to now31
- Board memberCam Gallagher Apr 3, 2020 to May 31, 202432
- Board memberDavid E. Goel Apr 3, 2020 to Apr 3, 202033
- Board memberKaran S. Takhar Apr 3, 2020 to Apr 3, 202034
- Board memberKimberly Blackwell Jul 1, 2020 to Feb 5, 202435
- General counselJames B. Bucher Sep 22, 2025 to now36
- General counselAndrea Paul Aug 1, 2022 to Feb 5, 202537
- General counselAlexis Pinto Sep 1, 2020 to Feb 14, 202238
Former names
Timeline
- Aug 14, 20268-K Other events39
- Aug 6, 20268-K Results of operations; Regulation FD disclosure40
- Jun 18, 20268-K Shareholder vote41
- May 27, 20268-K Executive or director change42
- May 21, 20268-K Regulation FD disclosure; Other events43
- May 12, 20268-K Results of operations; Regulation FD disclosure44
- May 5, 20268-K Regulation FD disclosure; Other events45
- Apr 17, 20268-K Regulation FD disclosure46
- Apr 9, 20268-K Regulation FD disclosure; Other events47
- Mar 26, 20268-K Results of operations48
- Jan 9, 20268-K Regulation FD disclosure; Other events49
- Dec 15, 20258-K Executive or director change; Other events50
- Nov 13, 2024New chief executive Julia Marie Eastland becomes CEO12
- May 20, 2022New chief executive Kimberly Blackwell becomes CEO13
Calendar
Coming up
- Nov 9, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.37) a share, on Nov 10, 2025.51
When it reported results
- Aug 6, 2026Reported quarterly or annual results40
- May 12, 2026Reported quarterly or annual results44
- Mar 26, 2026Reported quarterly or annual results48
- Nov 10, 2025Reported quarterly or annual results52
- Aug 6, 2025Reported quarterly or annual results53
- May 14, 2025Reported quarterly or annual results54
- Mar 26, 2025Reported quarterly or annual results55
- Aug 9, 2024Reported quarterly or annual results56
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
384 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 76 major events, 162 insider forms, 60 large holders, 65 other. The latest 20:
- Oct 1, 20264 EDGAR
- Aug 19, 2026SCHEDULE 13G/A EDGAR
- Aug 19, 20264 EDGAR
- Aug 14, 20268-K EDGAR
- Aug 14, 2026424B5 EDGAR
- Aug 13, 2026424B5 EDGAR
- Aug 13, 2026SCHEDULE 13G/A EDGAR
- Aug 6, 202610-Q EDGAR
- Aug 6, 20268-K EDGAR
- Jul 30, 2026SCHEDULE 13G EDGAR
- Jun 18, 20264 EDGAR
- Jun 18, 20264 EDGAR
- Jun 18, 20264 EDGAR
- Jun 18, 20268-K EDGAR
- Jun 18, 20264 EDGAR
- Jun 18, 20264 EDGAR
- May 27, 20264 EDGAR
- May 27, 20263 EDGAR
- May 27, 2026DEFA14A EDGAR
- May 27, 20268-K EDGAR
The 384 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
114 open-market trades by officers, directors and large owners since October 2021: 10 buys and 104 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 14, 2026 | WALTERS WILLIAM THURMAN10% owner | Buy | 4,335,000 | $3.50 | $15.2M | Form 4 |
| Feb 10, 2026 | Vultaggio VincentPAO and PFO | Sale | 6,894 | $2.42 | $16.7K | Form 4 |
| Feb 9, 2026 | Vultaggio VincentPAO and PFO | Sale | 3,379 | $2.39 | $8.1K | Form 4 |
| Feb 9, 2026 | Bruns IngmarChief Medical Officer | Sale | 335 | $2.39 | $801 | Form 4 |
| Feb 9, 2026 | EASTLAND JULIA MARIECEO & President | Sale | 889 | $2.39 | $2.1K | Form 4 |
| Feb 6, 2026 | Vultaggio VincentPAO and PFO | Sale | 29,951 | $2.43 | $72.8K | Form 4 |
| Feb 6, 2026 | Bruns IngmarChief Medical Officer | Sale | 2,962 | $2.43 | $7.2K | Form 4 |
| Feb 6, 2026 | EASTLAND JULIA MARIECEO & President | Sale | 7,866 | $2.43 | $19.1K | Form 4 |
| Feb 3, 2026 | Vultaggio VincentPAO and PFO | Sale | 556 | $2.52 | $1.4K | Form 4 |
| Feb 2, 2026 | Vultaggio VincentPAO and PFO | Sale | 2,540 | $2.55 | $6.5K | Form 4 |
| Dec 31, 2025 | WALTERS WILLIAM THURMAN10% owner | Buy | 6,459,973 | $1.20 | $7.8M | Form 4 |
| Dec 15, 2025 | GOEL DAVID E.10% owner | Sale | 7,500,000 | $1.33 | $10.0M | Form 4 |
| Apr 30, 2025 | Myers Scott DunsethDirector | Buy | 21,000 | $1.40 | $29.4K | Form 4 |
| Feb 6, 2025 | Bruns IngmarChief Medical Officer | Buy | 20,000 | $2.28 | $45.6K | Form 4 |
| Feb 3, 2025 | Vultaggio VincentPAO and PFO | Sale | 2,615 | $1.71 | $4.5K | Form 4 |
| Feb 3, 2025 | Lackner MarkChief Scientific Officer | Sale | 14,368 | $1.71 | $24.6K | Form 4 |
| Feb 3, 2025 | Paul AndreaChief Legal Officer | Sale | 13,230 | $1.71 | $22.6K | Form 4 |
| Jan 31, 2025 | Skvarka JanDirector | Buy | 60,000 | $1.72 | $103.2K | Form 4 |
| Jan 31, 2025 | Walker Luke NathanielDirector | Buy | 14,200 | $1.76 | $25.0K | Form 4 |
| Jan 31, 2025 | EASTLAND JULIA MARIECEO & President | Buy | 28,500 | $1.73 | $49.3K | Form 4 |
All 114 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- WALTERS GROUPSCHEDULE 13G/A, 2 filings Jan 5, 2026 to Aug 19, 202657
- BarclaysSCHEDULE 13G/A, 2 filings Nov 12, 2025 to Aug 13, 202658
- BlackRockSCHEDULE 13G, 5 filings Feb 3, 2022 to Jul 30, 202659
- Squadron Capital Management LLCSCHEDULE 13G, 1 filing Mar 3, 202660
- Matrix Capital Management Company, LPSCHEDULE 13D/A, 5 filings Feb 14, 2022 to Jan 2, 202661
- 5AM Opportunities II (GP), LLCSCHEDULE 13G, 1 filing Dec 30, 202562
- MILLENNIUM MANAGEMENT LLCSCHEDULE 13G/A, 2 filings Feb 4, 2025 to Oct 14, 202563
- EVENTIDE ASSET MANAGEMENT, LLCSCHEDULE 13G/A, 6 filings Oct 10, 2023 to May 14, 202564
- VANGUARD GROUP INCSCHEDULE 13G/A, 6 filings Feb 10, 2022 to Jan 31, 202565
- William Thurman WaltersSCHEDULE 13G/A, 4 filings Dec 10, 2024 to Jan 31, 202566
- FMR LLCSCHEDULE 13G/A, 5 filings Feb 9, 2022 to Dec 6, 202467
- CITADEL ADVISORS LLCSC 13G/A, 3 filings Nov 17, 2023 to Nov 14, 202468
- State Street CorporationSC 13G/A, 3 filings Feb 7, 2023 to Oct 18, 202469
- Avidity Partners Management LPSC 13G/A, 3 filings Feb 1, 2022 to Feb 13, 202470
- Capital International InvestorsSC 13G/A, 2 filings Feb 13, 2023 to Feb 9, 202471
- Wellington Management CompanySC 13G/A, 2 filings Feb 6, 2023 to Feb 9, 202472
- Anthony Y. SunSC 13G/A, 1 filing Mar 10, 202373
- PRICE T ROWE ASSOCIATES INC /MD/SC 13G/A, 2 filings Feb 14, 2022 to Feb 14, 202374
- TYBOURNE CAPITAL MANAGEMENT (HK) LTDSC 13G, 2 filings Feb 14, 2022 to Feb 14, 202375
- Redmile Group, LLCSC 13G/A, 1 filing Feb 14, 202276
- VIKING GLOBAL INVESTORS LPSC 13G/A, 1 filing Feb 14, 202277
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Andrea PaulFormer Chief Legal Officer and Corporate Secretary | $376.9K | $3.0M78 | |
| 2025 | Julie EastlandPresident and Chief Executive Officer | 62 | $700.0K | $1.3M78 |
| 2025 | Mark Lackner, Ph.D.Former Chief Scientific Officer | $153.6K | $1.2M78 | |
| 2025 | Ingmar Bruns, M.D.Chief Medical Officer | 51 | $530.0K | $869.8K78 |
| 2025 | James BucherChief Legal Officer and Corporate Secretary | 60 | $144.2K | $660.0K78 |
| 2024 | Julie EastlandPresident and Chief Executive Officer | 62 | $94.2K | $8.2M78 |
| 2024 | Mark Lackner, Ph.D.Former Chief Scientific Officer | $484.4K | $4.8M78 | |
| 2024 | Andrea PaulFormer Chief Legal Officer and Corporate Secretary | $502.3K | $3.7M78 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| 5AM Venture Management, LLC | 3,947,913 | $19.1M | 6.7% | No change |
| BlackRock, Inc. | 3,753,525 | $18.2M | 0.0% | +2,483,688 |
| Squadron Capital Management LLC | 3,700,000 | $17.9M | 6.1% | +69,000 |
| Two Sigma Investments, LP | 3,024,936 | $14.7M | 0.0% | +68,410 |
| Vanguard Capital Management LLC | 2,835,669 | $13.8M | 0.0% | +524,962 |
| Citadel Advisors LLC | 2,298,403 | $11.1M | 0.0% | +566,320 |
| Renaissance Technologies LLC | 1,609,078 | $7.8M | 0.0% | −329,067 |
| Opaleye Management Inc. | 1,412,656 | $6.9M | 0.6% | No change |
| Orbimed Advisors LLC | 1,390,576 | $6.7M | 0.1% | New |
| Decheng Capital LLC | 1,323,327 | $6.4M | 0.9% | No change |
| Geode Capital Management, LLC | 1,284,117 | $6.2M | 0.0% | +663,081 |
| Bank Of America Corp /de/ | 1,114,650 | $5.4M | 0.0% | −17,644 |
| Ishara Investments LP | 1,025,000 | $5.0M | 3.7% | −205,000 |
| Primecap Management Co/ca/ | 957,420 | $4.6M | 0.0% | No change |
| Soleus Capital Management, L.P. | 950,000 | $4.6M | 0.2% | New |
| State Street Corp | 887,416 | $4.3M | 0.0% | +637,726 |
| Vanguard Portfolio Management LLC | 808,548 | $3.9M | 0.0% | +447,948 |
| Pfizer Inc | 953,834 | $3.9M | 2.3% | No change |
| Connor, Clark & Lunn Investment Management Ltd. | 758,033 | $3.7M | 0.0% | −33,968 |
| Millennium Management LLC | 664,281 | $3.2M | 0.0% | −625,541 |
| ADAR1 Capital Management, LLC | 652,750 | $3.2M | 0.1% | +508,114 |
| Marshall Wace, Llp | 591,473 | $2.9M | 0.0% | +198,830 |
| Qube Research & Technologies Ltd | 574,806 | $2.8M | 0.0% | −62,310 |
| D. E. Shaw & Co., Inc. | 546,566 | $2.7M | 0.0% | −937,532 |
| Dimensional Fund Advisors LP | 542,852 | $2.6M | 0.0% | +270,818 |
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How Zentalis Pharmaceuticals, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARZentalis Pharmaceuticals, Inc.1
- CIK0001725160
- Employer ID (EIN)82-36078033
- Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company3
- Incorporated inDelaware3
- Fiscal year endsDecember 311
- Industry code (SIC)2834 Pharmaceutical Preparations1
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
- Business address10275 Science Center Drive, Suite 200, San Diego, CA 921211
- Phone(858) 263-43331
- Shares outstanding71,671,914 as of Aug 3, 202610
- Public float$66.9M as of Jun 30, 20253
- AuditorErnst & Young LLP, San Diego, California PCAOB ID 42; no auditor attestation of internal control over financial reporting3
- On EDGAR sinceDec 19, 20171
- Filings545 in all: 4 (221), 8-K (89), SC 13G/A (31), 3 (28), 144 (22), 10-Q (20), SC 13G (18), SCHEDULE 13G/A (13)1
All 40 form types
DEFA14A (12), CORRESP (10), UPLOAD (9), 424B5 (7), 10-K (6), DEF 14A (6), SCHEDULE 13G (6), S-8 (5), ARS (4), 4/A (3), EFFECT (3), S-1/A (3), 424B4 (2), 8-K/A (2), D (2), DRS (2), S-1 (2), S-3 (2), S-3ASR (2), SCHEDULE 13D/A (2), SEC STAFF LETTER (2), 10-K/A (1), 8-A12B (1), CERT (1), DRS/A (1), DRSLTR (1), FWP (1), PRE 14A (1), RW (1), S-1MEF (1), SC 13D (1), SC 13D/A (1)
- Latest filingsAnnual report (10-K) Mar 26, 2026
Quarterly report (10-Q) Aug 6, 2026
Proxy statement (DEF 14A) Apr 30, 2026
Latest 8-K (8-K) Aug 14, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common stock,$0.001 par value per share | ZNTL | The Nasdaq Global Market |
From the cover page of the 10-K filed Mar 26, 2026 (Section 12(b) of the Exchange Act).3
Risk factors and legal proceedings
The risks Zentalis Pharmaceuticals, Inc. names in Item 1A of its 10-K filed Mar 26, 2026: 75 risks under these headings, as written.3
- Risks Related to Our Financial Position and Need for Additional Capital
- We have a limited operating history and have no products approved for commercial sale, which may make it difficult for you to evaluate our current business and predict our future success and viability.
- We have incurred significant net losses since inception, and we expect to continue to incur significant net losses for the foreseeable future.
- Our ability to generate product revenue and achieve profitability depends significantly on our ability to achieve a number of objectives.
- We will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs or future commercialization efforts.
- Risks Related to the Discovery, Development and Commercialization of Our Product Candidates
- We are substantially dependent on the success of azenosertib, which is currently our only product candidate in clinical development. If we are unable to complete development of, obtain approval for and commercialize azenosertib in a timely manner, our business will be harmed.
- We have and in the future may enter into collaborations with third parties for the research, development and commercialization of certain of the product candidates we may develop. If any of these collaborations are not successful, we may not be able to capitalize on the market potential of those product candidates.
- Our long-term prospects depend in part upon discovering, developing and commercializing additional product candidates, which may fail in development or suffer delays that adversely affect their commercial viability.
- The regulatory approval processes of the FDA and ex-U.S. regulatory authorities are lengthy, time consuming and inherently unpredictable. If we are ultimately unable to obtain regulatory approval for azenosertib or any future product candidates, we will be unable to generate product revenue and our business will be substantially harmed.
- The clinical trials of azenosertib or any future product candidates may not demonstrate safety and efficacy to the satisfaction of the FDA or ex-U.S. regulatory authorities or otherwise produce positive results.
- Interim, initial, “topline,” and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.
The other 64 risks
- Even if approved, azenosertib and any future product candidates may not achieve adequate market acceptance among physicians, patients, healthcare payors and others in the medical community necessary for commercial success.
- If we experience delays or difficulties in the enrollment and/or continuing participation of patients in clinical trials, our clinical development activities could be delayed or otherwise adversely affected.
- A fast track designation from the FDA may not lead to a faster development or regulatory review or approval process, and does not increase the likelihood that our product candidates will receive regulatory approval.
- We are developing azenosertib in combination with other therapies, which exposes us to additional risks.
- If the market opportunity for azenosertib or any future product candidate that we or our strategic partners develop is smaller than we believe, our revenue may be adversely affected and our business may suffer.
- We face significant competition, and if our competitors develop and market technologies or products more rapidly than we do or that are more effective, safer or less expensive than the product candidates we develop, our commercial opportunities will be negatively impacted.
- We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.
- Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay.
- Our business entails a significant risk of product liability and if we are unable to obtain sufficient insurance coverage such inability could have an adverse effect on our business and financial condition.
- Any product candidates we develop may become subject to unfavorable third-party coverage and reimbursement practices, as well as pricing regulations.
- Risks Related to Regulatory Approval and Other Legal Compliance Matters
- We may be unable to obtain U.S. or ex-U.S. regulatory approvals and, as a result, may be unable to commercialize azenosertib or any future product candidates.
- Azenosertib or any future product candidates may cause significant AEs, toxicities or other undesirable side effects when used alone or in combination with other approved products or investigational new drugs that may result in a safety profile that could inhibit regulatory approval, prevent market acceptance, limit their commercial potential or result in significant negative consequences.
- The FDA and ex-U.S. regulatory authorities may not accept data from trials conducted in locations outside of their jurisdiction.
- Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.
- Even if our product candidates receive regulatory approval, they will be subject to significant post-marketing regulatory requirements and oversight.
- The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses.
- Changes and/or disruptions at the FDA, the SEC and other government agencies, including as a result of government shutdowns, funding shortages, staffing changes or limitations, or global health concerns could prevent those agencies from performing business functions as they were previously performed, which could negatively impact our business.
- If we are unable to obtain accelerated approval or any other form of expedited development or review from the FDA or ex-U.S. regulatory authorities, we may be required to conduct additional clinical trials beyond those that we contemplate, which could increase the expense of obtaining, and delay the receipt of, necessary marketing approvals. Even if we receive accelerated approval from the FDA, if our confirmatory trials do not verify clinical benefit, or if we do not comply with rigorous post-marketing requirements, the FDA may seek to withdraw accelerated approval.
- Current and future healthcare reform legislation or regulation may increase the difficulty and cost for us to commercialize any approved product candidate and may adversely affect the prices we may obtain and may have a negative impact on our business and results of operations.
- Our relationships with healthcare professionals, clinical investigators, CROs and third party payors in connection with our current and future business activities may be subject to fraud and abuse laws and other healthcare laws and regulations.
- Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect our business, results of operations, and financial condition.
- Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, CMOs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.
- If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on our business.
- Our research and development activities could be affected or delayed as a result of possible restrictions on animal testing.
- Our business activities may be subject to the U.S. Foreign Corrupt Practices Act, or the FCPA, and similar anti-bribery and anti-corruption laws of other countries in which we operate, as well as U.S. and certain ex-U.S. export controls, trade sanctions, and import laws and regulations. Compliance with these legal requirements could limit our ability to compete in ex-U.S. markets and subject us to liability if we violate them.
- Risks Related to Employee Matters, Managing Our Growth and Other Risks Related to Our Business
- Our success is highly dependent on our ability to attract and retain highly skilled executive officers and employees.
- If we are unable to establish effective sales or marketing capabilities or enter into agreements with third parties to sell or market our product candidates, we may not be able to successfully sell or market our product candidates that obtain regulatory approval.
- In order to successfully implement our long-term plans and strategies, we will need to grow the size of our organization, and we may experience difficulties in managing this growth.
- Our business and operations may suffer in the event of information technology system failures, cyberattacks or deficiencies in our cybersecurity.
- Ex-U.S. pricing, drug marketing and reimbursement regulations may materially affect our ability to market and receive coverage for our products in the European member states.
- Unfavorable U.S., global, political or economic conditions could adversely affect our business, financial condition or results of operations.
- Scrutiny and changing expectations from governments and other stakeholders with respect to Environmental, Social and Governance, or ESG, policies and practices may cause us to incur additional costs or expose us to additional risks.
- Business interruptions could adversely affect our operations.
- Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.
- A variety of risks associated with marketing our product candidates internationally could materially adversely affect our business.
- If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks.
- The requirements of being a public company may strain our resources, result in more litigation and divert management’s attention.
- A portion of our manufacturing of azenosertib takes place in ex-U.S. countries, including China, through third-party manufacturers. A significant disruption in the operation of those manufacturers, a trade war or political unrest in such ex-U.S. countries, including China, could materially adversely affect our business, financial condition and results of operations.
- Risks Related to Our Intellectual Property
- Our success depends on our ability to protect our intellectual property and our proprietary platform.
- If we fail to comply with our obligations in the agreements under which we license intellectual property rights from our licensors and third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.
- If the scope of our patent protection or any patent protection our licensors obtain is not sufficiently broad, or if our licensors lose any of the patent protection we license, our ability to prevent our competitors from commercializing similar or identical product candidates would be adversely affected.
- The patent protection and patent prosecution for some of our product candidates may be dependent on our licensors and third parties.
- Some of our intellectual property may be subject to federal regulations such as “march-in” rights, certain reporting requirements and a preference for U.S.-based companies if it is determined that our intellectual property has been discovered through government-funded programs. Compliance with such regulations may limit our exclusive rights, and limit our ability to contract with non-U.S. manufacturers.
- Intellectual property rights do not necessarily address all potential threats to our competitive advantage.
- Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties. Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts.
- We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful. Further, our issued patents or the patents of our licensors could be found invalid or unenforceable if challenged in court.
- Intellectual property litigation may lead to unfavorable publicity that harms our reputation and causes the market price of our common shares to decline.
- Derivation or interference proceedings may be necessary to determine priority of inventions, and an unfavorable outcome may require us to cease using the related technology or to attempt to license rights from the prevailing party.
- Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our or our licensors' patent applications and the enforcement or defense of our or our licensors' issued patents.
- Changes in U.S. patent law, or laws in other countries, could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.
- We or our licensors may be subject to claims challenging the inventorship or ownership of our or our licensors' patents and other intellectual property.
- Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.
- If we or our licensors do not obtain patent term extension for azenosertib and any future product candidates, our business may be materially harmed.
- We may not be able to protect our intellectual property rights throughout the world.
- If we are unable to protect our trade secrets, our business and competitive position would be harmed.
- Risks Related to Our Dependence on Third Parties
- We rely, and expect to continue to rely, on third parties, including independent clinical investigators and CROs, to conduct certain aspects of our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties, comply with applicable regulatory requirements or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize azenosertib or any future product candidates and our business could be substantially harmed.
- We contract with third parties for the manufacture of azenosertib for preclinical studies and ongoing clinical trials, and expect to continue to do so for additional clinical trials and ultimately for commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of azenosertib or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.
- The manufacture of drugs is complex and our third-party manufacturers may encounter difficulties in production. If any of our third-party manufacturers encounter such difficulties, our ability to provide adequate supply of our product candidates for clinical trials or our products for patients, if approved, could be delayed or prevented.
- If we decide to establish collaborations in the future, but are not able to establish those collaborations on commercially reasonable terms, we may have to alter our development and commercialization plans.
- Risks Related to Ownership of Our Common Stock
- The price of our stock may be volatile, and you could lose all or part of your investment.
- Our quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline.
- Our principal stockholders and management own a significant percentage of our stock and are able to exert significant influence over matters subject to stockholder approval.
- Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall.
Legal proceedings
We are not subject to any material legal proceedings.
The opening of Item 3, Legal Proceedings.3
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14SEC EDGARCam Gallagher, President
- 15
- 16
- 17SEC EDGARIris Roth, Chief operating officer
- 18
- 19
- 20SEC EDGARDiana Hausman, Chief Medical Officer
- 21
- 22SEC EDGARIngmar Bruns, Chief Medical Officer
- 23
- 24
- 25
- 26SEC EDGARShannon Campbell, Board member
- 27SEC EDGARLuke Nathaniel Walker, Board member
- 28SEC EDGARScott Dunseth Myers, Board member
- 29SEC EDGARDiana Hausman, Board member
- 30SEC EDGARJan Skvarka, Board member
- 31SEC EDGAREnoch Kariuki, Board member
- 32SEC EDGARCam Gallagher, Board member
- 33SEC EDGARDavid E. Goel, Board member
- 34SEC EDGARKaran S. Takhar, Board member
- 35SEC EDGARKimberly Blackwell, Board member
- 36SEC EDGARJames B. Bucher, General counsel
- 37SEC EDGARAndrea Paul, General counsel
- 38SEC EDGARAlexis Pinto, General counsel
- 39SEC EDGAROther events
- 40
- 41SEC EDGARShareholder vote
- 42SEC EDGARExecutive or director change
- 43
- 44
- 45
- 46SEC EDGARRegulation FD disclosure
- 47
- 48SEC EDGARResults of operations
- 49
- 50
- 51NasdaqNasdaq calendar
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78